Endoscopy 2021; 53(S 01): S143-S144
DOI: 10.1055/s-0041-1724640
Abstracts | ESGE Days
ESGE Days 2021 Digital poster exhibition

Spatz 3 Adjustable Balloon System: Feasibility, Efficacy And Safety Issues Of A Dual Center Experience

G de Nucci
1   ASST Rhodense, Gastroenterology and Endoscopy Unit, Garbagnate Milanese (MI), Italy
,
C Simeth
2   ASUGI, Gastroenterology Unit, Trieste, Italy
,
R Reati
3   AORN Cardarelli, Gastroenterology and Endoscopy Unit, Napoli, Italy
,
ED Mandelli
4   ASST Rhodense, Gastroenterology and Endoscopy Unit, Milan, Italy
,
D Redaelli
1   ASST Rhodense, Gastroenterology and Endoscopy Unit, Garbagnate Milanese (MI), Italy
,
D Morganti
1   ASST Rhodense, Gastroenterology and Endoscopy Unit, Garbagnate Milanese (MI), Italy
,
E Colombo
5   ASST Rhodense, Internal Medicine Department, Garbagnate Milanese, Italy
,
C d’Urbano
6   ASST Rhodense, General Surgery Unit, Garbagnate Milanese (MI), Italy
,
SA Berra
5   ASST Rhodense, Internal Medicine Department, Garbagnate Milanese, Italy
,
F Monica
2   ASUGI, Gastroenterology Unit, Trieste, Italy
,
G Manes
1   ASST Rhodense, Gastroenterology and Endoscopy Unit, Garbagnate Milanese (MI), Italy
› Author Affiliations
› Further Information
Also available at
 
 

    Aims Intragastric balloons for weight loss and as bridge to major bariatric surgery are effective tools, but they could be associated with early period intolerance and a diminished effect within 8-12 weeks. The introduction of an adjustable balloon could improve comfort and offer greater efficacy over the time. Spatz 3 is a dynamic bariatric device with a long implantation time (12 months), system for inflation/deflation of the balloon, and safety mechanism for bowel migration despite an eventual deflation. There are few data about its efficacy and safety in a large followed up bariatric population.

    Methods The aim of our study was to assess Spatz3 efficacy in terms of weight loss and safety issues. Implantations of Spatz 3 in 138 patients were reviewed and data about demographics, weight loss, bridging to surgery, early and late complications were collected from the prospectively collected database of two tertiary Endoscopic centers. Mean age of the study population was 47,8 years and its mean starting BMI was 40,2. A 12 months treatment was scheduled and volume adjustment was proposed in case of patient intolerance or weight loss plateau.

    Results From January 2016 to April 2019, 138 patients were treated with Spatz 3 ballon endoscopic implantation and among these 71 used the treatment as bridge to major surgery. The mean weight loss period was 24.8 kilograms. In 8 pts the device was removed after 3 weeks for intolerance. Down volume adjustment was performed in 9 pts allowing them to continue the therapy, volume balloon increase was instead performed in 19 pts yielding an additional mean weight loss of 4.8 kilograms. No Spatz rupture, gastric perforations o major clinic complications occurred.

    Conclusions Spatz 3 balloon seems to be an effective device to treat obesity with a significant weight loss within a 12 months period with no early or late complication.

    Citation de Nucci G, Simeth C, Reati R et al. eP144 SPATZ 3 ADJUSTABLE BALLOON SYSTEM: FEASIBILITY, EFFICACY AND SAFETY ISSUES OF A DUAL CENTER EXPERIENCE. Endoscopy 2021; 53: S143.


    #

    Publication History

    Article published online:
    19 March 2021

    © 2021. European Society of Gastrointestinal Endoscopy. All rights reserved.

    Georg Thieme Verlag KG
    Rüdigerstraße 14, 70469 Stuttgart, Germany